Keck School Faculty

Howard Silberman, MD
Howard Silberman, MD
Professor of Surgery
Surgery
1510 San Pablo St. Health Sciences Campus Los Angeles
Dr. Howard Silberman, Professor of Surgery at the Keck School of Medicine of the University of Southern California, was awarded the M.D. degree by the Jefferson Medical College in Philadelphia and received his postgraduate training in surgery at the Hospital of the University of Pennsylvania. He is a Diplomate of the American Board of Surgery, a Fellow of the American College of Surgeons, and has been elected to membership in various professional organizations, including the Society of University Surgeons, the American Society of Clinical Oncology, the Society of Surgical Oncology, the American Society of Breast Surgeons, the Society for Surgery of the Alimentary Tract, and the American Society for Parenteral and Enteral Nutrition. As a member of the full-time Attending Staff of the USC/Norris Cancer Hospital, Dr. Silberman specializes in the management of breast cancer as well as tumors of the gastrointestional tract and malignant melanoma. He serves as the Associate Director of the Harold E. and Henrietta C. Lee Breast Center at the USC/Norris Comprehensive Cancer Center and Hospital. He also attends in the Division of Tumor and Endocrine Surgery at the Los Angeles County-USC Medical Center. Dr. Silberman’s clinical interests are reflected in his book, Principles and Practice of Surgical Oncology: Multidisciplinary Approach to Difficult Problems. This work considers the management of patients with complicated, advanced, or unusual tumors of the stomach, pancreas, small intestine, colon, rectum, and soft tissues including breast cancer, melanoma, and sarcoma. The text emphasizes a combined multidisciplinary approach (drug therapy, radiotherapy, and surgery) to the treatment of cancer. Dr. Silberman also has a long standing interest in surgical nutrition and is the author of text Parenteral and Enteral Nutrition.

Modified Bi-Rads Scoring of Breast Imaging Findings Improves Clinical Judgment Breast J. 2015 Nov-Dec; 21(6):642-50. . View in PubMed

Update and Review on the Surgical Management of Primary Cutaneous Melanoma Healthcare (Basel). 2014 Jun 10; 2(2):234-49. . View in PubMed

Image of the month-quiz case Arch Surg. 2012 Sep 01; 147(9). . View in PubMed

Image of the month-quiz caseDiagnosis: primary adenocarcinoma. Arch Surg. 2012 Sep; 147(9):887-8. . View in PubMed

Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast Am J Surg. 2006 Oct; 192(4):420-2. . View in PubMed

Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast Am J Surg. 2006 Oct; 192(4):416-9. . View in PubMed

Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Am J Surg. 2005 Oct; 190(4):521-5. . View in PubMed

Perioperative adjunctive treatment in the management of operable gastric cancer J Surg Oncol. 2005 Jun 01; 90(3):174-86; discussion 186-7. . View in PubMed

Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast Am J Surg. 2004 Oct; 188(4):371-6. . View in PubMed

MammoSite radiation therapy system Breast. 2003 Dec; 12(6):491-6. . View in PubMed

Breast-conserving therapy for ductal carcinoma in situ: a 20-year experience with excision plus radiation therapy Am J Surg. 2002 Nov; 184(5):403-9. . View in PubMed

Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer Am J Surg. 2002 Oct; 184(4):337-40. . View in PubMed

Palpable breast cancers are inherently different from nonpalpable breast cancers Ann Surg Oncol. 2001 Oct; 8(9):705-10. . View in PubMed

Phase I and pharmacologic study of iv. hydroxyurea infusion given with i. p. 5-fluoro-2'-deoxyuridine and leucovorin. Anticancer Drugs. 2001 Jul; 12(6):505-11. . View in PubMed

Breast cancer after augmentation mammoplasty Ann Surg Oncol. 2001 Mar; 8(2):138-44. . View in PubMed

Preoperative paclitaxel and radiotherapy for locally advanced breast cancer: surgical aspects Ann Surg Oncol. 2000 Mar; 7(2):145-9. . View in PubMed

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J Clin Oncol. 1998 Jan; 16(1):309-16. . View in PubMed

Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy Int J Radiat Oncol Biol Phys. 1997 Dec 01; 39(5):1059-68. . View in PubMed

Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer Am J Surg. 1997 Dec; 174(6):705-7; discussion 707-8. . View in PubMed

Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report Cancer. 1997 May 01; 79(9):1767-75. . View in PubMed

Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival J Clin Oncol. 1996 Jan; 14(1):176-82. . View in PubMed

Bowel obstruction in cancer patients Arch Surg. 1995 Aug; 130(8):832-6; discussion 836-7. . View in PubMed

Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial Eur J Cancer. 1995 Jul-Aug; 31A(7-8):1306-10. . View in PubMed

Comparative study of infectious complications of different types of chronic central venous access devices Cancer. 1994 Jun 01; 73(11):2832-7. . View in PubMed

Chronic venous access in patients with cancerSelective use of the saphenous vein. Cancer. 1993 Aug 01; 72(3):760-5. . View in PubMed

Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program J Clin Oncol. 1992 Dec; 10(12):1933-42. . View in PubMed

Prospective evaluation of a double-lumen subclavian dialysis catheter for acute vascular access Am Surg. 1992 Aug; 58(8):443-5. . View in PubMed

The in vivo availability of gentamicin when admixed with total nutrient solutions: a comparative study JPEN J Parenter Enteral Nutr. 1990 Sep-Oct; 14(5):523-6. . View in PubMed

Absorbable versus permanent mesh in abdominal operations Surg Gynecol Obstet. 1989 Mar; 168(3):227-32. . View in PubMed

A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers J Clin Oncol. 1988 Jun; 6(6):1053-8. . View in PubMed

The relation of thyroid indices in the critically ill patient to prognosis and nutritional factors Surg Gynecol Obstet. 1988 Mar; 166(3):223-8. . View in PubMed

Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics Cancer Res. 1988 Jan 15; 48(2):459-61. . View in PubMed

Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment J Clin Oncol. 1986 Jun; 4(6):888-99. . View in PubMed

Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma Blood. 1984 Mar; 63(3):639-48. . View in PubMed

Effects of age on responses to treatment and survival of patients with multiple myeloma J Am Geriatr Soc. 1983 May; 31(5):272-7. . View in PubMed

Assessment of myeloma maintenance regimen of prednisoneAdriamycin, imuran, and vincristine in a murine plasmacytoma model. Cancer Clin Trials. 1981; 4(2):135-41. . View in PubMed

Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma Blood. 1979 Oct; 54(4):824-36. . View in PubMed

Powered by SC CTSI
Go to Top